Intravenous (IV) Ibuprofen Global Market Report 2025
상품코드:1751028
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 175 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
이부프로펜 정맥주사(IV) 시장 규모는 향후 수년간 급성장이 예상됩니다. 노화, 첨단 의약품 치료의 채택 증가 등 여러 요인에 기인하고 있습니다. 이 기간의 주요 동향으로는 고급 치료 솔루션의 개발, 일회 투여 제제의 출현, 맞춤형 의료의 진전, 다제 병용에 의한 통증 관리 프로토콜에의 통합, 병용 요법의 진전 등을 들 수 있습니다.
통증 장애의 유병률 증가는 향후 몇 년 동안 이부프로펜 정맥주사(IV) 시장의 성장을 가속할 것으로 예측됩니다. 통증 장애의 증가는 주로 인구 고령화에 기인합니다. 노인들은 관절염, 골관절염, 신경통과 같은 만성 질환에 걸릴 가능성이 높기 때문에 효과적인 통증 완화에 대한 수요가 높아집니다. 2024년 1월 영국의 건강 개선 및 격차 해소 사무소는 장기적인 근골격계 질환을 가지고 있다고 자기 신고한 16세 이상의 사람의 비율이 2022년의 17.6%에서 2023년에는 18.4%로 증가했다고 보고했습니다.
이부프로펜 정맥주사(IV) 시장의 각 회사는 오피오이드 의존 위험을 줄이면서 통증 관리를 개선하기 위해 오피오이드가 없는 진통제와 같은 고급 제제 개발에 주력하고 있습니다. 진정한 진통제는 오피오이드를 포함하지 않는 진통제로 중독과 오피오이드 관련 부작용의 위험을 제거 할 수 있습니다. 예를 들어 2024년2월영국 제약 회사 Hikma Pharmaceuticals plc는 2023년 10월 FDA 승인에 이어 미국에서 COMBOGESIC IV(아세트아미노펜, 이부프로펜) 주사제를 발매했습니다. 오피오이드를 포함하지 않는 이 정맥 진통제는 경도에서 중등도의 통증의 완화, 중등도로부터 중증의 통증 관리의 보조를 목적으로 합니다. COMBOGESIC IV는 의료 종사자에게 새로운 비 오피오이드 진통 솔루션을 제공합니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 태와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 이부프로펜 정맥주사(IV) PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 이부프로펜 정맥주사(IV) 시장 : 성장률 분석
세계의 이부프로펜 정맥주사(IV) 시장 실적: 규모와 성장, 2019년-2024년
세계의 이부프로펜 정맥주사(IV) 시장 예측 : 규모와 성장, 2024년-2029년, 2034년
세계의 이부프로펜 정맥주사(IV) 전체 시장 규모(TAM)
제6장 시장 세분화
세계의 이부프로펜 정맥주사(IV) 시장 :제품 유형별, 분석과 예측, 2019년-2024년, 2024년-2029년, 2034년
종래의 이부프로펜 정맥주사(IV)
고농도 이부프로펜 정맥주사(IV)
세계의 이부프로펜 정맥주사(IV) 시장 : 함유량별, 분석과 예측, 2019년-2024년, 2024년-2029년, 2034년
100밀리그램(mg)
200밀리그램(mg)
400밀리그램(mg)
800밀리그램(mg)
세계의 이부프로펜 정맥주사(IV) 시장 : 연령층별, 분석과 예측, 2019년-2024년, 2024년-2029년, 2034년
소아과
성인
세계의 이부프로펜 정맥주사(IV) 시장 : 용도별, 분석과 예측, 2019년-2024년, 2024년-2029년, 2034년
통증
열
염증
기타 용도
세계의 이부프로펜 정맥주사(IV) 시장 : 최종 사용자별, 분석과 예측, 2019년-2024년, 2024년-2029년, 2034년
병원
외래수술센터(ASC)
클리닉
기타 최종 사용자
세계의 이부프로펜 정맥주사(IV) 시장 : 종래의 정맥내(IV) 이부프로펜유형별 세분화, 분석과 예측, 2019년-2024년, 2024년-2029년, 2034년
소아과용 이부프로펜 정맥주사(IV)
성인용 이부프로펜 정맥주사(IV)
세계의 이부프로펜 정맥주사(IV) 시장 : 고농도 정맥내(IV) 이부프로펜유형별 세분화, 분석과 예측, 2019년-2024년, 2024년-2029년, 2034년
일회 투여 바이알
멀티 도즈 바이알
제7장 지역별/국가별 분석
세계의 이부프로펜 정맥주사(IV) 시장 : 지역별, 분석과 예측, 2019년-2024년, 2024년-2029년, 2034년
세계의 이부프로펜 정맥주사(IV) 시장 : 국가별, 분석과 예측, 2019년-2024년, 2024년-2029년, 2034년
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
이부프로펜 정맥주사(IV) 시장 : 경쟁 구도
이부프로펜 정맥주사(IV) 시장 : 기업 프로파일
Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Sanofi SA : 개요, 제품 및 서비스, 전략 및 재무 분석
Novartis AG : 개요, 제품 및 서비스, 전략 및 재무 분석
Fresenius SE & Co. KGaA : 개요, 제품 및 서비스, 전략 및 재무 분석
Teva Pharmaceutical Industries Ltd. : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Baxter International
Mylan NV
Sandoz Group AG
Grifols SA
Dr. Reddy's Laboratories
Hikma Pharmaceuticals plc
CSL Limited
Eurolife Healthcare Pvt. Ltd.
B. Braun Holding GmbH & Co. KG
AFT Pharmaceuticals Ltd
Cumberland Pharmaceuticals Inc.
Delex Pharma International Inc.
Recordati Rare Diseases Inc.
Xgen Pharmaceuticals Djb Inc.
Wellona Pharma
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
이부프로펜 정맥주사(IV) 시장 2029년 : 새로운 기회를 제공하는 국가
이부프로펜 정맥주사(IV) 시장 2029년 : 새로운 기회를 제공하는 부문
이부프로펜 정맥주사(IV) 시장 2029년 : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
SHW
영문 목차
영문목차
Intravenous (IV) Ibuprofen is a medication administered directly into the bloodstream through an intravenous route, primarily used for providing rapid pain relief and reducing inflammation or fever, especially in patients who are unable to take oral medications. It works by inhibiting the production of prostaglandins, which are responsible for causing pain and inflammation. IV ibuprofen is commonly used in clinical settings, particularly for postoperative pain and other acute conditions that require quick relief.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main product types in the intravenous (IV) ibuprofen market include conventional intravenous (IV) ibuprofen and high-concentration intravenous (IV) ibuprofen. Conventional intravenous (IV) ibuprofen is the standard formulation used to administer ibuprofen directly into the bloodstream for pain relief, inflammation reduction, and fever management, typically in hospital settings for acute or postoperative pain. The available strengths for intravenous ibuprofen include 100 mg, 200 mg, 400 mg, and 800 mg. IV ibuprofen is used for a range of conditions, including pain, fever, and inflammation, across different age groups, including pediatrics and adults. The key end-users include hospitals, ambulatory surgical centers, clinics, and other healthcare settings.
The intravenous (IV) ibuprofen market research report is one of a series of new reports from The Business Research Company that provides intravenous (IV) ibuprofen market statistics, including intravenous (IV) ibuprofen industry global market size, regional shares, competitors with a intravenous (IV) ibuprofen market share, detailed intravenous (IV) ibuprofen market segments, market trends and opportunities, and any further data you may need to thrive in the intravenous (IV) ibuprofen industry. This intravenous (IV) ibuprofen market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The intravenous (IV) ibuprofen market size has grown rapidly in recent years. It will grow from$8.35 billion in 2024 to $9.4 billion in 2025 at a compound annual growth rate (CAGR) of 12.5%. The growth in the historic period can be attributed to several factors, including the increasing prevalence of chronic diseases, a rise in surgical procedures, and a growing emphasis on minimizing opioid usage.
The intravenous (IV) ibuprofen market size is expected to see rapid growth in the next few years. It will grow to$14.86 billion in 2029 at a compound annual growth rate (CAGR) of 12.1%. The growth during the forecast period can be attributed to several factors, including higher healthcare investments, a growing pediatric patient population, an increase in the prevalence of pain and fever, an aging population, and a rise in the adoption of advanced pharmaceutical treatments. Key trends during this period include the development of advanced therapeutic solutions, the emergence of single-dose formulations, progress in personalized medicine, integration into multimodal pain management protocols, and advancements in combination therapies.
The growing prevalence of pain disorders is expected to drive the growth of the intravenous ibuprofen market in the coming years. Pain disorders are medical conditions characterized by persistent or chronic pain that impairs daily functioning, often due to nerve, musculoskeletal, or inflammatory issues. The increase in pain disorders is largely attributed to the aging population, as older adults are more likely to develop chronic conditions such as arthritis, osteoarthritis, and nerve pain, leading to a higher demand for effective pain relief. Intravenous ibuprofen aids pain management by providing rapid relief, making it particularly suitable for acute and postoperative pain. It works by reducing inflammation and enhancing patient comfort, improving the overall effectiveness of treatment in medical settings. For example, in January 2024, the Office for Health Improvement and Disparities in the UK reported that the percentage of individuals aged 16 and older who self-reported having a long-term musculoskeletal condition increased to 18.4% in 2023, up from 17.6% in 2022. As a result, the rising prevalence of pain disorders is contributing to the growth of the intravenous ibuprofen market.
Companies in the intravenous ibuprofen market are focusing on developing advanced drug formulations, such as opioid-free analgesics, to improve pain management while reducing the risk of opioid dependence. An opioid-free analgesic is a pain-relieving medication that does not contain opioids, thereby eliminating the risks of addiction and opioid-related side effects. For instance, in February 2024, Hikma Pharmaceuticals plc, a UK-based pharmaceutical company, introduced COMBOGESIC IV (acetaminophen and ibuprofen) injection in the U.S. following FDA approval in October 2023. This intravenous, opioid-free analgesic is intended for the relief of mild to moderate pain and as an adjunct for managing moderate to severe pain. By combining two active ingredients with distinct mechanisms of action, COMBOGESIC IV offers a novel non-opioid pain management solution for healthcare providers.
In May 2024, Halex Istar Industria Farmaceutica SA, a Brazil-based pharmaceutical company, entered into a partnership with AFT Pharmaceuticals Ltd. to expand the distribution of Maxigesic IV (paracetamol + ibuprofen IV) in Brazil. This collaboration aims to provide effective non-opioid pain management solutions to the Brazilian market. AFT Pharmaceuticals Ltd., based in New Zealand, specializes in intravenous pain relief products.
Major players in the intravenous (iv) ibuprofen market are Pfizer Inc., Sanofi S.A., Novartis AG, Fresenius SE & Co. KGaA, Teva Pharmaceutical Industries Ltd., Baxter International, Mylan N.V., Sandoz Group AG, Grifols S.A., Dr. Reddy's Laboratories, Hikma Pharmaceuticals plc, CSL Limited, Eurolife Healthcare Pvt. Ltd., B. Braun Holding GmbH & Co. KG, AFT Pharmaceuticals Ltd, Cumberland Pharmaceuticals Inc., Delex Pharma International Inc., Recordati Rare Diseases Inc., Xgen Pharmaceuticals Djb Inc., Wellona Pharma, and Hyloris Pharmaceuticals SA.
North America was the largest region in the intravenous (IV) ibuprofen market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in intravenous (IV) ibuprofen report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the intravenous (IV) ibuprofen market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The intravenous (IV) ibuprofen market consists of sales of pediatric intravenous (IV) ibuprofen, intravenous (IV) ibuprofen concentrate and pre-mixed intravenous (IV) ibuprofen bags. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Intravenous (IV) Ibuprofen Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on intravenous (iv) ibuprofen market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for intravenous (iv) ibuprofen ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The intravenous (iv) ibuprofen market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
3. Intravenous (IV) Ibuprofen Market Trends And Strategies
4. Intravenous (IV) Ibuprofen Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Intravenous (IV) Ibuprofen Growth Analysis And Strategic Analysis Framework
5.1. Global Intravenous (IV) Ibuprofen PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Intravenous (IV) Ibuprofen Market Growth Rate Analysis
5.4. Global Intravenous (IV) Ibuprofen Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Intravenous (IV) Ibuprofen Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Intravenous (IV) Ibuprofen Total Addressable Market (TAM)
6. Intravenous (IV) Ibuprofen Market Segmentation
6.1. Global Intravenous (IV) Ibuprofen Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Conventional Intravenous (IV) Ibuprofen
High-Concentration Intravenous (IV) Ibuprofen
6.2. Global Intravenous (IV) Ibuprofen Market, Segmentation By Strength, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
100 Milligrams (mg)
200 Milligrams (mg)
400 Milligrams (mg)
800 Milligrams (mg)
6.3. Global Intravenous (IV) Ibuprofen Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pediatrics
Adults
6.4. Global Intravenous (IV) Ibuprofen Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pain
Fever
Inflammation
Other Applications
6.5. Global Intravenous (IV) Ibuprofen Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Ambulatory Surgical Centers
Clinics
Other End-Users
6.6. Global Intravenous (IV) Ibuprofen Market, Sub-Segmentation Of Conventional Intravenous (IV) Ibuprofen, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pediatric Intravenous (IV) Ibuprofen
Adult Intravenous (IV) Ibuprofen
6.7. Global Intravenous (IV) Ibuprofen Market, Sub-Segmentation Of High-Concentration Intravenous (IV) Ibuprofen, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Single-Dose Vial
Multi-Dose Vial
7. Intravenous (IV) Ibuprofen Market Regional And Country Analysis
7.1. Global Intravenous (IV) Ibuprofen Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Intravenous (IV) Ibuprofen Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
